Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab
https://www.facingourrisk.org/research-clinical-trials/study/135/treating-metastatic-pancreatic-cancer-with-an-inherited-or-tumor-brca12-or-palb2-mutation-with-niraparib-and-dostarlimab
Clinicaltrials.gov identifier:
NCT04493060 (https://clinicaltrials.gov/show/NCT04493060)
Study Contact Information:
Contact the Mayo Clinic Clinical Trials Referral Office by phone 855-776-0015 or by email.
Principal Investigator: Robert R. McWilliams, MD
About the Study
This study looks at how well the PARP inhibitor niraparib and the immunotherapy drug dostarlimab work together in treating patients with metastatic pancreatic cancer, who also have an inherited or tumor mutation in one of the following genes: BRCA1, BRCA2, PALB2, BARD1, RAD51c, or RAD51d.
- Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Immunotherapy such as dostarlimab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
This study is no longer enrolling people.
This Study is Open To:
This study is no longer enrolling people.
This Study is Not Open To:
This study is no longer enrolling people.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.